1-(3-Chlorophenyl)piperazine HCl
CAS: 65369-76-8
Ref. 3D-FC20352
| 10g | 136.00 € | ||
| 25g | 180.00 € | ||
| 50g | 270.00 € | ||
| 100g | 407.00 € | ||
| 250g | 678.00 € |
Estimated delivery in United States, on Friday 13 Dec 2024
Product Information
Name:
1-(3-Chlorophenyl)piperazine HCl
Controlled Product
Synonyms:
- 1-(m-Chlorophenyl)piperazine HCl4-(3-Chlorophenyl)piperazine HClN-(3-Chlorophenyl)piperazine HCl
- 1-(3-Chlorophenyl)Piperazine Hydrochloride
- 1-(3-Chlorophenyl)Piperazine Hydrochloride (1:1)
- 1-(3-Chlorophenyl)Piperazine Monohcl
- 1-(3-Chlorophenyl)piperazine monohydrochloride
- 1-(m-Chlorophenyl)piperazine hydrochloride
- Piperazine, 1-(3-chlorophenyl)-, hydrochloride
- Piperazine, 1-(3-chlorophenyl)-, hydrochloride (1:?)
- Piperazine, 1-(3-chlorophenyl)-, monohydrochloride
- Piperazine, 1-(m-chlorophenyl)-, hydrochloride
- See more synonyms
Description:
1-(3-Chlorophenyl)piperazine HCl is a drug that belongs to the group of pharmacological agents. It is used as an antidepressant and antipsychotic, and has been shown to decrease serotonin levels in the brain. 1-(3-Chlorophenyl)piperazine HCl is a potent 5-HT2C receptor agonist that inhibits ovarian activity in vitro. The compound has also been shown to be effective against trazodone and 5-HT2 receptors in vitro.
Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Biosynth
Long term storage:
Notes:
Chemical properties
Molecular weight:
233.14 g/mol
Formula:
C10H14Cl2N2
Purity:
Min. 95 Area-%
Color/Form:
White Powder
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: 3D-FC20352 1-(3-Chlorophenyl)piperazine HCl
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
